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EVALUATION OF A NUTRACEUTICAL JOINT SUPPLEMENT IN CRANES
KENDRA L. BAUER, University of Wisconsin-Madison, School of Veterinary Medicine, 2015 Linden Drive, Madison, WI 53706, 
USA
ELLEN S. DIERENFELD, Novus International, Inc., 20 Research Park Drive, St. Charles, MO 63304, USA
BARRY K. HARTUP, International Crane Foundation, E-11376 Shady Lane Road, Baraboo, WI 53913, USA
Abstract: Osteoarthritis is a problem that threatens the reproductive capabilities of captive populations of endangered cranes. 
In our pilot study, we used 5 cranes with a history of unilateral, chronic tarsal pathology in a cross-over design to gauge the 
effects of the primary ingredient (NEM®, ESM Technologies LLC, Carthage, MO) of the nutraceutical Steadfast® (Novus 
Nutrition Brands, LLC, St. Charles, MO). We evaluated the ingredient for acceptance, safety, and short-term efficacy. To 
evaluate efficacy, we collected goniometric measures to determine range of motion in each tarsal joint before and after a 5-week 
experimental period where NEM® was offered in pelleted feed. We also determined time spent in locomotion from estimates 
of activity once per week. The ingredient was determined to be both acceptable as offered and apparently was safe for the 
cranes. There were no significant changes in the birds’ weights or body condition scores during any period of the trial. There 
was a significant increase in overall tarsal flexion measurements in the 5 birds’ affected legs (P = 0.04), and 1 bird showed +14 
degrees of improvement in flexion. No changes were seen in measures of tarsal extension or in either measure in unaffected 
legs. The behavioral data was inconclusive due to the small sample size and large variation in the weekly estimates within 
individuals. Though there was evidence of increased joint mobility in all birds in this small pilot study, further study is needed 
to determine if NEM® is efficacious for managing osteoarthritis in cranes. 
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Musculoskeletal abnormalities are prevalent in 
cranes. A retrospective survey at the International 
Crane Foundation (ICF), Baraboo, Wisconsin, 
showed musculoskeletal problems were the second 
leading cause of morbidity in whooping cranes (Grus 
americana) (Hartup et al. 2010). Known etiologies for 
avian lameness include infection, endocrine imbalance, 
developmental problem, nutritional deficiency, or 
trauma (Curro et al. 1992). Cranes have long life spans; 
if an injury occurs early in life, a crane may face chronic 
problems for many years with repercussions affecting 
individual welfare, reproduction, and conservation 
goals. Recurring mild lameness is often a sign of 
progressive osteoarthritis, also known as degenerative 
joint disease (Olsen et al. 1996). Osteoarthritis may 
lead to declines in joint function and captive breeding 
success; for example, by limiting proper incubation 
postures and lowering hatchability of naturally 
incubated eggs (Gabel and Mahan 1996).
Current therapy for degenerative arthropathies 
in cranes typically involves administration of non-
steroidal anti-inflammatory drugs (NSAIDs) and 
changes in husbandry (Olsen et al. 1996, Cole et al. 
2009). However, NSAIDs may not be suitable for long-
term therapy. Mild hemorrhage of the proventricular 
mucosa has been documented in some cranes with short- 
and long-term exposure to meloxicam and piroxicam, 
respectively. Renal lesions have also been noted 
postmortem in cranes dosed with flunixin meglumine 
while at ICF. Siberian cranes (Grus leucogeranus) 
and whooping cranes administered varying levels of 
flunixin meglumine were diagnosed with visceral gout 
at necropsy (ICF unpublished data). Mortality occurred 
in 4 of 5 Siberian cranes and 1 of 4 whooping cranes 
given flunixin meglumine. No side effects or mortality 
were noted in other crane species administered flunixin 
meglumine, including blue cranes (Anthropoides 
paradiseus), hooded cranes (G. monacha), sandhill 
cranes (G. canadensis), and sarus cranes (G. antigone). 
Steadfast® is a nutraceutical supplement currently 
marketed for dogs and horses to improve joint health 
by providing relief from discomfort and promoting 
mobility (Novus Nutrition Brands, LLC, St. Charles, 
MO). It is composed of eggshell membrane (NEM®, 
ESM Technologies LLC, Carthage, MO), organic 
chelated trace minerals, antioxidant vitamins, and 
other nutrients that support joint, bone, and connective 
tissue health (Dierenfeld et al. 2010). The NEM® 
includes components such as collagen, hyaluronic acid, 
glucosamine, chondroitin sulfate, durmatan sulfate, 
desmosine, amino acids, and peptides. Dierenfeld et al. 
(2010) measured levels of the cartilage blood biomarker 
CTX-II to evaluate the efficacy of Steadfast® in camels. 
The decrease in levels of this cartilage marker has been 
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shown to correlate with a decrease in inflammation 
and increased weight bearing in rats (Wedekind et al. 
2010). However, it is unknown whether this biomarker 
is present in avian species since the composition of 
avian cartilage is different than that of mammals. Avian 
articular cartilage contains high levels of both collagen 
I and collagen II; the primary collagen in articular 
cartilage is collagen II in mammals (Eyre et al. 1978). 
Despite the differences in cartilage composition, there 
are many morphological and biochemical similarities 
between degenerative joint disease in mammalian and 
avian species (Anderson-Mackenzie et al. 1997). These 
similarities suggest that Steadfast® may also have some 
benefit in degenerative joint disease in birds.
This pilot study was conducted to determine the 
acceptance, safety, and potential efficacy of NEM®, 
and to determine if a larger trial is warranted. We 
expected birds to show improvements in joint health as 
evidenced by increased range of motion of the affected 
joint and increased locomotion behavior during the 
course of the study.
METHODS
Five cranes with chronic tarsal abnormalities were 
used in this study (Table 1). The birds were housed 
with mates in 15 × 18-m outdoor pens covered by flight 
netting with chain-link fencing along each side and 
grass covered soil as a substrate. Each pen included a 
4.2 × 4.2-m indoor enclosure with a deep bedding of 
wood shavings over concrete substrate. Pelleted food 
and fresh water were provided ad libitum in buckets in 
the enclosures (Hartup and Schroeder 2006).
We used a cross-over study design where cranes 
received either the NEM® ingredient in their diet at 
800 ppm (0.08% in reconstituted crane maintenance 
pellets, Zeigler Brothers Inc., Gardners, PA) or a 
placebo diet (original pellets without NEM®) for 5 
weeks, followed by a 2-week washout period (placebo 
diet). The cranes then received the opposite treatment 
for an additional 5 weeks. Each crane served as its own 
control while on the placebo diet. Though the study was 
designed to be blinded, an unexpected food shortage in 
the experimental diet caused the researcher to become 
un-blinded. Since all cranes in the study were part of 
a breeding pair and food was shared, both pen mates 
received NEM®. Food was weighed before and after 
each feeding to determine the amount removed. Given 
that we could not determine the exact amount eaten by 
each member of the pair, we assumed that each crane 
ate half of the food removed from the feed bucket. 
The first trial period took place from 12 July 2010 to 
15 August 2010; the second from 30 August 2010 to 3 
October 2010.
On day 0 and day 35 of each 5-week period, 
specific data were collected. A physical examination 
was performed (by B. Hartup), with special attention 
paid to the hind limb joints. Each crane was weighed 
and assigned a body condition index (BCI) score 
(1-5 scale, 1 = minimal pectoral muscle mass with 
prominent sternum, 5 = robust, well rounded pectoral 
muscle mass, sternum palpated with difficulty) (Olsen 
et al. 1996). Also, the range of motion of each crane’s 
tarsal joints was measured with a goniometer (Fig. 1). 
This measurement was taken by either K. Bauer or B. 
Hartup. A goniometer measurement of 180° was defined 
as a full flexion while a measurement of 0° was defined 
as full extension. A total of 4 measurements were 
taken: full flexion of the right leg, full extension of the 
right leg, full flexion of the left leg, and full extension 
of the left leg. Measurements were taken by aligning 
the fulcrum of the goniometer with the center of the 
tarsal joint. Gentle pressure was applied to the joint to 
achieve either full extension or full flexion. One arm of 
the goniometer was aligned parallel with the tibia and 
the other with the tarsometatarsus. To our knowledge, 
this is the first documentation of this methodology to 
determine range of motion in avian tarsal joints.
In addition, digital video cameras already present 
at ICF were used to monitor the movements of the 
Table 1. Summary of the cranes used in the nutraceutical trial.
ID Species Age (years) Sex Musculoskeletal problem
Bubba Grus americana 26 M Slipped tendon (left tarsus)
Rattler G. americana 42 M Degenerative arthritis (left tarsus)
Dushenka G. leucogeranus 29 M Slipped tendon (left tarsus)
Kavir G. leucogeranus 16 F Previous injury to lateral collateral ligament (right tarsus)
Ranjit G. leucogeranus 24 F Slipped tendon (left tarsus)
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birds for 50 minutes per week during each 5-week 
period on a randomly selected day and time between 
0700 and 1000 hours. This footage was assessed 
by 1 of 2 individuals, either K. Bauer or an intern 
aviculturist trained by K. Bauer, in order to record 
an activity budget of each crane, accounting for what 
percentage of time each crane spent in daily activities 
such as walking or resting. To decrease inter-observer 
variability, both observers participated in practice 
observation sessions. Behaviors for this activity 
budget were placed into 1 of 5 categories: foraging, 
locomotion, comfort, resting, or social interaction. If 
the crane spent time in its house, which was outside 
of the view of the camera, the behavior was recorded 
as out of sight. A behavior was recorded every 30 
seconds during the 50 minute period for each crane, 
for a total of 100 data points. If the crane was recorded 
as out of sight for more than 40 of those data points, 
the data was discarded and the crane was given a new 
observation time for the week. If insufficient data 
points were again recorded, the 2 sets of data from the 
2 observations periods were combined.
A food shortage shortened 1 crane’s experimental 
period. The crane received the diet through day 16 of 
the 5-week period, and its final evaluation took place on 
day 17 of the trial period. Behavior data was collected 
for the first 3 weeks of this period.
The primary author was blinded to the treatment 
assigned each crane during the 2 5-week periods. We 
used unpaired t-tests to compare food consumption 
between periods among the cranes. Normal distributions 
were confirmed by visual inspection and review of 
skewness and kurtosis calculations on each set of 
treatment and control data and deemed acceptable. To 
analyze the goniometry data, BCI scores, and weights, 
we used a nonparametric Wilcoxon signed-rank test for 
paired samples (Statview 5.0.1, SAS Institute, Inc, Cary, 
NC). The Wilcoxon test is an alternative to the paired 
t-test applicable to small datasets and uses a ranking 
of differences between each pair of observations. The 
resultant Z-statistic tests the hypothesis that the sum 
of the ranks is equal to 0, assuming the distribution 
of ranks is symmetric around 0. The larger positive or 
negative number reflects greater differences between 
paired values. Statistical significance was established at 
P < 0.05.
RESULTS
Acceptance and Safety
Four of 5 individuals consumed significantly less 
of the experimental diet than the placebo diet, while the 
fifth individual consumed more of the experimental diet 
than the placebo diet (all P < 0.01, Table 2). Because 
the experimental diet was reconstituted in order to 
incorporate the nutraceutical product, the resulting feed 
did not maintain its cylindrical shape well. Each crane 
pair regularly reduced their experimental diet to a fine 
dust, but the placebo pellets always remained intact. 
This led to more frequent replacement and/or sifting of 
the experimental diet pellets, and ultimately led to the 
depletion of the experimental diet supply. 
During the physical examinations at the end of 
the experimental diet period, 2 birds were diagnosed 
with additional abnormalities. One bird had developed 
pododermatitis (bumblefoot), and another had increased 
lateral instability in the tarsus, possibly due to an acute 
lateral collateral ligament injury. Both abnormalities 
occurred in the previously unaffected leg. No significant 
differences were observed in weights (P = 0.58) or BCI 
scores (P = 0.29) taken at day 35 of each period (Table 3).
Efficacy
We detected significant differences in baseline 
flexion and extension measurements between the 
Figure 1. Goniometry measurement of tarsal flexion in a crane.
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cranes’ affected and unaffected legs taken at days 0 
and 35 of the placebo diet period and day 0 of the 
experimental diet period (both P < 0.01, Table 4). 
After 35 days of consumption of the experimental 
diet, there was a significant change in the flexion 
measurements of the affected leg among the 5 cranes 
(P = 0.04), but not the extension measurements (P = 
0.72, Table 5). No significant changes were observed 
in the measurements for the unaffected leg of any 
crane post-treatment. 
Behavior varied greatly from week to week for each 
crane both on the experimental and the control diet. No 
identifiable trends were observed for the amount of time 
the cranes spent in locomotion during the experimental 
diet period.
DISCUSSION
Acceptance and Safety
Overall, we believe that the diet containing NEM® 
was well accepted by the cranes used in this trial and 
appeared safe. The addition of the NEM® altered the 
normal delivery of the pellets, i.e., pellets containing 
NEM® were quickly reduced to crumbles. It may also 
have altered the palatability of the pellets. Overall, the 
amount of experimental diet consumed by the cranes 
was lower compared to placebo diet for 4 of the 5 
cranes. This could have been due to modest rejection 
based on taste, or more likely, the reconstitution process 
and poor binding resulted in the cranes’ inability to 
handle a more fragile pellet. We believe the food 
consumption results are best explained, however, by 
what we believe is an increase in food consumption in 
response to seasonal change. The 4 cranes with greater 
placebo diet intake did so in the second 5-week period 
of the study (early fall), and the 1 crane that consumed 
more experimental diet was the only bird to receive it 
in the latter period as well, all perhaps reflecting the 
first stages of migration readiness behavior. Regardless, 
no cranes experienced significant change in weight 
or body condition. Additional monitoring, including 
hematology and blood chemistry analysis, would be of 
benefit in future trials.
Table 2. Mean ± SD daily pelleted feed intake (g) of individual 
birds during 2 trial periods.
ID Placebo diet Experimental diet
Bubba 165 ± 38 126 ± 33
Rattler 138 ± 27 173 ± 36
Dushenka 200 ± 38 180 ± 29
Kavir 185 ± 44 151 ± 31
Ranjit 202 ± 64 164 ± 46
Table 3. Weights (kg) and body condition scores (1-5 scale) 
of individuals following 35 days consumption of either a 
placebo or experimental diet containing a nutraceutical joint 
supplement.
ID Weight, placebo diet
Weight, 
experimental 
diet
BCI, 
placebo diet
BCI, 
experimental 
diet
Bubba 4.9 5.2 2 2.5
Rattler 5.6 5.6 2 2
Dushenka 6.6 6.4 4 2.5
Kavir 4.9 4.8 4 3
Ranjit 5.8 5.5 3 3
Table 4. Control goniometry (in degrees, mean ± SD) based on 
3 measurements from unaffected and affected legs of 5 cranes 
with chronic tarsal abnormalities. An overall decreased range 
of motion in the affected legs of the birds is reflected in lower 
flexion and greater extension measurements.
Unaffected leg Affected leg
Flexion 169.3 ± 6.8 152.8 ± 18.4
Extension 6.5 ± 2.6 9.6 ± 4.8
Table 5. Goniometry measurements (in degrees) from each bird’s affected leg following 35 days consumption of either a placebo 
or experimental diet containing a nutraceutical joint supplement.
ID Leg flexion,  placebo diet
Leg flexion, 
experimental diet
Leg extension,  
placebo diet
Leg extension, 
experimental diet
Bubba 145 150 11 8
Rattler 158 163 7 4
Dushenka 157 166 15 15
Kavir 173 175 2 0
Ranjit 120 135 6 11
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The fragility of the reconstituted diet was a problem 
in this study because 2 of the cranes had pre-existing 
beak malocclusions requiring greater food depths for 
successful consumption from buckets. A well-bound 
pellet would have mitigated this issue, but the cranes 
still appeared to meet their nutritional needs. Feeding 
the cranes tablets hidden in treats was not an option 
due to the malocclusions, as well as the overall lack of 
prior training of these subjects. In well-trained birds 
without complicating beak injuries, direct dosing using 
treats may be a viable option (Dierenfeld et al. 2010). 
Including the NEM® in the original extrusion and 
pelleting would likely result in a more durable product 
at delivery.
We noted no acute or systemic adverse effects at 
the concentration and route of NEM® administered. 
However, the safety of NEM® cannot be definitely 
determined due to a lack of hematologic and biochemical 
data. We are uncertain whether NEM® supplementation 
was associated with new musculoskeletal conditions 
diagnosed in 2 of the cranes during the experimental 
period, though it seems unlikely. The conditions 
emerged in the contralateral leg to the original, 
chronically affected leg in each crane. Normally these 
types of conditions occur secondarily when cranes 
place undue weight on a good leg while minimizing 
weight bearing on an affected leg. We hypothesized just 
the opposite: birds with improved joint function from 
NEM® supplementation would begin to bear weight 
in a more balanced manner and be less susceptible to 
injury or development of secondary musculoskeletal 
disease. Unfortunately, weight bearing distribution was 
not assessed in this study. If the birds were in fact still 
compensating for their chronically injured leg, it is less 
likely that they had truly improved joint health as a 
result of the NEM® added to their diet. A full treatment 
effect also seems less likely with the short duration of 
the treatment period.
Efficacy
We observed modest improvement in goniometry 
measurements relative to joint flexion, but not extension, 
in cranes with an abnormal leg that were provided 
a nutraceutical joint supplement for 5 weeks. The 
improvement in abnormal tarsal joint range of motion 
was approximately 5%. A more thorough comparison 
to younger individuals of the studied species would 
provide useful reference data. A longer trial with the 
same individuals or additional cases would serve to 
validate this product’s potential for mitigating the 
progression and complications of osteoarthritis and 
musculoskeletal injuries common to cranes in captive 
environments.
We did not discern any semi-quantitative change 
in locomotion behavior in the cranes. The behavior 
data collected was likely insufficient in frequency 
and duration to accurately determine the locomotion 
budget for a given crane and determine an effect of 
the nutraceutical supplement. Activity budget data is 
notoriously variable day-to-day, and often highly biased 
by lack of observation when birds are out of sight. In 
addition, our observations coincided with a seasonal 
change that might also have affected activity levels 
(early fall). We suggest that any future trials include a 
long-term behavioral assessment as well as direct range 
of motion assessments within a single prolonged season 
(e.g., immediately post-breeding to fall) or across an 
annual cycle.
A primary challenge for further studies will 
be production of a processed diet containing the 
nutraceutical that can withstand normal delivery and 
field conditions encountered when feeding captive 
cranes. Additionally, full assessment of the therapeutic 
impact of NEM® will need assessment using multiple 
methods and over a longer time period. Other options 
for future trials include testing a therapeutic approach 
combining the use of NEM® with another product such 
as an NSAID.
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